Completed PHASE4 INTERVENTIONAL 2-arm NCT02276196

Effect of LIXIsenatide on the Renal System (ELIXIRS)

A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus

Sponsor: Amsterdam UMC, location VUmc

Conditions Diabetes Mellitus Diabetic Kidney Disease Diabetic Nephropathy Glucagon-Like Peptide 1

Interventions Insulin glulisine Lixisenatide

Updated 6 times since 2017 Last updated: Apr 28, 2016 Started: Sep 30, 2014 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Diabetes Mellitus and Diabetic Kidney Disease and is currently completed. Amsterdam UMC, location VUmc leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
May 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — May 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amsterdam UMC, location VUmc

Data source: Amsterdam UMC, location VUmc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands